Search
Merck's Application for Marketing Authorization of Pimicotinib Approved for Giant Cell Tumor of Tendon Sheath Treatment
2025-06-10 /
Read about 0 minute
Author：小编
The Center for Drug Evaluation of China's National Medical Products Administration has accepted Merck's application for marketing authorization of Pimicotinib, an innovative class 1 drug. This medication is designed to treat adult patients diagnosed with giant cell tumor of the tendon sheath who require systemic therapy. Concurrently, Merck is also progressing with its application for marketing authorization with the U.S. Food and Drug Administration (FDA) and intends to seek approval in other markets in a sequential manner.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
